Analyst Price Targets — TEVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 12, 2026 9:12 am | — | Barclays | $42.00 | $36.48 | TheFly | Teva price target raised to $42 from $40 at Barclays |
| July 28, 2026 10:45 am | David Amsellem | Piper Sandler | $44.00 | $31.08 | TheFly | Teva price target raised to $44 from $42 at Piper Sandler |
| May 6, 2026 9:48 am | — | Barclays | $40.00 | $35.86 | TheFly | Teva price target raised to $40 from $38 at Barclays |
| April 30, 2026 11:19 am | — | Piper Sandler | $42.00 | $35.38 | TheFly | Teva price target raised to $42 from $41 at Piper Sandler |
| April 30, 2026 10:55 am | — | UBS | $42.00 | $35.38 | TheFly | Teva price target raised to $42 from $36 at UBS |
| March 4, 2026 12:42 pm | David Amsellem | Piper Sandler | $41.00 | $32.64 | StreetInsider | Teva Pharma (TEVA) PT Raised to $41 at Piper Sandler; 'Much To Be Bullish About' |
| January 30, 2026 10:35 am | Glen Santangelo | Barclays | $38.00 | $33.07 | TheFly | Teva price target raised to $38 from $35 at Barclays |
| January 29, 2026 3:18 pm | — | Scotiabank | $40.00 | $32.90 | TheFly | Teva price target raised to $40 from $35 at Scotiabank |
| January 7, 2026 12:22 pm | — | Truist Financial | $36.00 | $32.11 | TheFly | Teva price target raised to $36 from $32 at Truist |
| January 6, 2026 12:37 pm | — | Jefferies | $40.00 | $31.00 | TheFly | Teva price target raised, named a top 2026 idea at Jefferies |
Latest News for TEVA
Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) on Wednesday reported encouraging topline outcomes from an active Phase 2a clinical trial evaluating TEV ‘408, an experimental anti-interleukin-15 monoclonal antibody, for celiac disease.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shares are trading higher after the company announced positive topline results from an ongoing Phase 2a study of TEV ‘408.
Teva Pharmaceutical Industries NYSE: TEVA reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company saying the treatment met its primary endpoint and showed statistically significant effects on key measures of intestinal damage.
Israeli drugmaker Teva Pharmaceutical Industries , said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of a mid-stage trial.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.